Summary
Aytu BioPharma (Nasdaq: AYTU) is a commercial-stage pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve patients’ quality of life. Aytu is committed to enhancing the lives of individuals affected by psychiatric conditions with the company’s innovative treatments for major depressive disorder and attention deficit/hyperactivity disorder and ensuring broad access for patients. Most recently, Aytu has acquired US commercial rights to a novel antidepressant called EXXUA™, an approved, first-in-class depression treatment not associated with the most common side effects of commonly prescribed antidepressants, most notably sexual side effects and weight gain. The company plans to launch EXXUA by the end of 2025. Along with EXXUA, the company also commercializes a portfolio of ADHD & pediatric brands generating over $65M in annual revenue and $9M in annual Adjusted EBITDA. The company is supported by long-term, healthcare-focused institutional investors, with Nantahala Capital as its largest shareholder.
Stock Chart
Investment Highlights
Management Profiles
Josh Disbrow CEO
Josh Disbrow’s career spans twenty-eight years across diverse, growing life sciences enterprises. Prior to co-founding Aytu in 2015, Josh was the CEO of Luoxis, a subsidiary of publicly listed Ampio Pharmaceuticals, where he jointly served as Ampio’s COO. Previously, he was VP of Commercial Operations at Arbor Pharmaceuticals, a pharmaceutical company he exited when a global private equity firm acquired a large equity stake in Arbor, valuing the company at over $1B. Josh joined Arbor as the second full-time employee and scaled commercial operations from inception to over $250 million in sales when he exited in 2012. He began his career in sales with GSK.
Josh serves on the board of Zynex, Inc. (Nasdaq: ZYXI) and is Chair of the Nominating; Corporate Governance Committee. Josh began his career in sales with GSK, and he holds an MBA from Wake Forest University and BS in Management from NC State University.